ES2607471T3
(es)
|
2002-11-18 |
2017-03-31 |
Roche Innovation Center Copenhagen A/S |
Diseño antisentido
|
WO2009023855A2
(en)
|
2007-08-15 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2009100320A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
US8426378B2
(en)
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
EP2285819B1
(de)
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
US8604192B2
(en)
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
HUE035888T2
(en)
|
2008-10-15 |
2018-05-28 |
Ionis Pharmaceuticals Inc |
Modulation of Factor 11 Expression
|
EP2358398A2
(de)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und verfahren
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
WO2010064146A2
(en)
|
2008-12-02 |
2010-06-10 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
MX2011013078A
(es)
|
2009-06-12 |
2012-02-01 |
Santaris Pharma As |
Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).
|
EP3643783A1
(de)
|
2009-06-17 |
2020-04-29 |
Biogen MA Inc. |
Zusammensetzungen und verfahren zur modulation der smn2-aufspaltung in einem patienten
|
IN2012DN00720A
(de)
|
2009-07-06 |
2015-06-19 |
Ontorii Inc |
|
US9012421B2
(en)
|
2009-08-06 |
2015-04-21 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8957040B2
(en)
|
2010-02-08 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP2534262B1
(de)
|
2010-02-08 |
2016-12-14 |
Ionis Pharmaceuticals, Inc. |
Selektive reduktion von allelvarianten
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2606057B1
(de)
|
2010-04-28 |
2016-06-15 |
Ionis Pharmaceuticals, Inc. |
Modifizierte 5' diphosphat-nukleoside und daraus hergestellte oligomere verbindungen
|
EP3173419A1
(de)
|
2010-04-28 |
2017-05-31 |
Ionis Pharmaceuticals, Inc. |
Modifizierte nukleoside, analoga davon und daraus hergestellte oligomere verbindungen
|
EP3091027B1
(de)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
BR112012027547B1
(pt)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2580228B1
(de)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
|
WO2012007477A1
(en)
|
2010-07-12 |
2012-01-19 |
Santaris Pharma A/S |
Anti hcv oligomers
|
DK3031920T3
(da)
|
2010-07-19 |
2019-10-14 |
Ionis Pharmaceuticals Inc |
Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
WO2012039448A1
(ja)
|
2010-09-24 |
2012-03-29 |
株式会社キラルジェン |
不斉補助基
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
WO2012064758A2
(en)
|
2010-11-08 |
2012-05-18 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
EP2640853B1
(de)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation von alpha-synukleinexpression
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
SG193504A1
(en)
|
2011-04-01 |
2013-10-30 |
Isis Pharmaceuticals Inc |
Modulation of signal transducer and activator of transcription 3 (stat3) expression
|
WO2012142458A1
(en)
|
2011-04-13 |
2012-10-18 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
EP3505528B1
(de)
|
2011-04-21 |
2020-11-25 |
Ionis Pharmaceuticals, Inc. |
Modulation einer hepatitis-b-virus (hbv)-expression
|
LT2702155T
(lt)
|
2011-04-25 |
2017-05-10 |
Regulus Therapeutics Inc. |
Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui
|
MY162715A
(en)
|
2011-04-27 |
2017-07-14 |
Ionis Pharmaceuticals Inc |
Modulation of apolipoprotein ciii (apociii) expression
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2012170947A2
(en)
|
2011-06-10 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
US9315811B2
(en)
|
2011-06-10 |
2016-04-19 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
WO2012174476A2
(en)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
US20140127159A1
(en)
|
2011-06-23 |
2014-05-08 |
Stella Aps |
HCV Combination Therapy
|
AU2012275096B2
(en)
|
2011-06-29 |
2016-02-04 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
EP2726611A1
(de)
|
2011-06-30 |
2014-05-07 |
Stella ApS |
Hcv-kombinationstherapie
|
JP2014520772A
(ja)
|
2011-06-30 |
2014-08-25 |
ステラ・アンパルトセルスカブ |
Hcv併用療法
|
RU2014105311A
(ru)
|
2011-07-19 |
2015-08-27 |
Уэйв Лайф Сайенсес Пте. Лтд. |
Способы синтеза функционализованных нуклеиновых кислот
|
WO2013022966A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
WO2013033223A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
BR112014006587B1
(pt)
|
2011-09-20 |
2021-07-27 |
Ionis Pharmaceuticals, Inc |
Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
|
IN2014CN03749A
(de)
|
2011-10-25 |
2015-09-25 |
Isis Pharmaceuticals Inc |
|
ES2607681T3
(es)
|
2011-11-07 |
2017-04-03 |
Roche Innovation Center Copenhagen A/S |
Método de pronóstico para comprobar la eficacia de inhibidores de micro ARN-122 en pacientes VHC+
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
US9725722B2
(en)
|
2011-11-07 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
Modulation of TMPRSS6 expression
|
JP2014533944A
(ja)
|
2011-11-11 |
2014-12-18 |
サンタリス ファーマ アー/エスSantaris Pharma A/S |
Smn2スプライシングの調節のための化合物
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
DK2794880T3
(en)
|
2011-12-22 |
2018-07-23 |
Ionis Pharmaceuticals Inc |
METHOD OF MODULATING METASTASE-ASSOCIATED-IN-LONG-ADENOCARCINOM TRANSCRIPT-1- (MALATE-1) EXPRESSION
|
ES2842938T3
(es)
|
2012-01-11 |
2021-07-15 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para la modulación del empalme de IKBKAP
|
EP2812342B1
(de)
|
2012-02-08 |
2017-11-15 |
Ionis Pharmaceuticals, Inc. |
Modulation von rna durch wiederholtes targeting
|
WO2013142514A1
(en)
|
2012-03-19 |
2013-09-26 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
CA2866392C
(en)
|
2012-03-30 |
2023-10-24 |
Washington University |
Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2013154798A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
EP3336189A1
(de)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
EP2841579B1
(de)
|
2012-04-25 |
2018-10-10 |
Regulus Therapeutics Inc. |
Mirna-verbindungen und verfahren zur modulation der mir-21-aktivität
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
US9518261B2
(en)
|
2012-05-22 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer RNA mediated gene expression
|
HUE051680T2
(hu)
|
2012-05-24 |
2021-03-29 |
Ionis Pharmaceuticals Inc |
Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013181666A2
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9617539B2
(en)
|
2012-06-25 |
2017-04-11 |
Ionis Pharmaceuticals, Inc. |
Modulation of UBE3A-ATS expression
|
PT2872485T
(pt)
|
2012-07-13 |
2021-03-05 |
Wave Life Sciences Ltd |
Grupo auxiliar assimétrico
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
CA2878945A1
(en)
|
2012-07-13 |
2014-01-16 |
Wave Life Sciences Pte. Ltd. |
Chiral control
|
US20150297629A1
(en)
|
2012-07-27 |
2015-10-22 |
Isis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
US9403865B2
(en)
|
2012-08-15 |
2016-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified capping protocols
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
EP2906699A4
(de)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
|
EP2906225B1
(de)
|
2012-10-11 |
2021-12-22 |
Ionis Pharmaceuticals, Inc. |
Eine modifizierte antisense-verbindung zur verwendung bei der behandlung der kennedy-krankheit
|
US20150275208A1
(en)
|
2012-10-12 |
2015-10-01 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US20160138014A1
(en)
|
2012-10-12 |
2016-05-19 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
PT2906696T
(pt)
|
2012-10-15 |
2019-12-16 |
Univ California |
Métodos para modular a expressão de c9orf72
|
US10443052B2
(en)
|
2012-10-15 |
2019-10-15 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating C9ORF72 expression
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
DK2920308T3
(en)
|
2012-10-31 |
2019-04-01 |
Ionis Pharmaceuticals Inc |
cancer Treatment
|
MX363068B
(es)
|
2012-11-15 |
2019-03-07 |
Roche Innovation Ct Copenhagen As |
Conjugados de oligonucleotido.
|
JP6463687B2
(ja)
|
2012-11-26 |
2019-02-06 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
Fgfr3の発現の調節のための組成物及び方法
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
CA2893801A1
(en)
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
US9701708B2
(en)
|
2013-01-31 |
2017-07-11 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
EP2951304B1
(de)
|
2013-02-04 |
2020-07-08 |
Ionis Pharmaceuticals, Inc. |
Selektive antisense-verbindungen und verwendungen davon
|
WO2014127268A2
(en)
|
2013-02-14 |
2014-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
|
JP6629716B2
(ja)
|
2013-03-14 |
2020-01-15 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
タウ発現を調節するための組成物および方法
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
JP2016518842A
(ja)
|
2013-05-01 |
2016-06-30 |
レグルス セラピューティクス インコーポレイテッド |
マイクロRNA化合物およびmiR−122をモジュレートする方法
|
NZ630921A
(en)
|
2013-05-01 |
2017-12-22 |
Regulus Therapeutics Inc |
Compounds and methods for enhanced cellular uptake
|
PL2992009T3
(pl)
|
2013-05-01 |
2020-11-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji apolipoproteiny(a)
|
BR112015029327A2
(pt)
|
2013-05-24 |
2017-09-19 |
Roche Innovation Ct Copenhagen As |
Moduladores de oligonucleotídeo de linfoma 11a/cll de célula b (bcl11a) e usos dos mesmos
|
ES2778462T3
(es)
|
2013-06-21 |
2020-08-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular expresión de C-III de apolipoproteína para mejorar un perfil diabético
|
EP3730619A1
(de)
|
2013-06-21 |
2020-10-28 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von zielnukleinsäuren
|
PE20160158A1
(es)
|
2013-06-27 |
2016-03-18 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en pcsk9
|
US20170073689A1
(en)
|
2013-07-02 |
2017-03-16 |
Ionis Pharmaceuticals, Inc. |
Modulators of growth hormone receptor
|
EP3022176B8
(de)
|
2013-07-15 |
2019-12-25 |
The Regents of the University of California |
Eingeschränkte azacyclische analoga von fty720
|
TW202246503A
(zh)
|
2013-07-19 |
2022-12-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
WO2015017675A2
(en)
|
2013-07-31 |
2015-02-05 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
SI3041854T1
(sl)
|
2013-08-08 |
2020-03-31 |
The Scripps Research Institute |
Postopek za mestnospecifično encimsko označevanje nukleinskih kislin in vitro z vključevanjem nenaravnih nukleotidov
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
NZ716816A
(en)
|
2013-08-28 |
2022-05-27 |
Ionis Pharmaceuticals Inc |
Modulation of prekallikrein (pkk) expression
|
MX371518B
(es)
|
2013-09-13 |
2020-01-31 |
Ionis Pharmaceuticals Inc |
Moduladores del factor del complemento b.
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
KR20160062069A
(ko)
|
2013-10-11 |
2016-06-01 |
아이오니스 파마수티컬즈, 인코포레이티드 |
C9orf72 발현을 조절하기 위한 조성물
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
WO2015061246A1
(en)
|
2013-10-21 |
2015-04-30 |
Isis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
WO2015061536A1
(en)
|
2013-10-25 |
2015-04-30 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-21 activity
|
DK3077510T3
(da)
|
2013-12-02 |
2020-06-08 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser og anvendelser deraf
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
EP3087183B1
(de)
|
2013-12-24 |
2020-08-26 |
Ionis Pharmaceuticals, Inc. |
Modulation einer angiopoietin-3-ähnlichen expression
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
CN106068325B
(zh)
|
2014-01-16 |
2021-07-09 |
波涛生命科学有限公司 |
手性设计
|
CA2938857A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
US9611479B2
(en)
*
|
2014-02-18 |
2017-04-04 |
Osaka University |
Crosslinked nucleoside and nucleotide
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
SG10201808063PA
(en)
|
2014-03-19 |
2018-10-30 |
Ionis Pharmaceuticals Inc |
Compositions for modulating ataxin 2 expression
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
US10385341B2
(en)
|
2014-04-01 |
2019-08-20 |
Biogen Ma Inc. |
Compositions for modulating SOD-1 expression
|
TWI638047B
(zh)
|
2014-04-09 |
2018-10-11 |
史基普研究協會 |
藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
EP3137476B1
(de)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomerverbindungen
|
EP4223315A3
(de)
|
2014-05-01 |
2023-08-23 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur synthese von reaktiven konjugatclustern
|
ES2812099T3
(es)
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
|
DK3137605T3
(da)
|
2014-05-01 |
2020-12-14 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
|
MX2016014140A
(es)
|
2014-05-01 |
2017-09-15 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de pkk.
|
RS59182B1
(sr)
|
2014-05-01 |
2019-10-31 |
Ionis Pharmaceuticals Inc |
Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
CN112301031A
(zh)
|
2014-05-22 |
2021-02-02 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
RU2017105342A
(ru)
|
2014-08-07 |
2018-09-13 |
Регулус Терапьютикс Инк. |
НАЦЕЛИВАНИЕ НА микроРНК ПРИ РАССТРОЙСТВАХ ОБМЕНА ВЕЩЕСТВ
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
EP3201339A4
(de)
|
2014-10-03 |
2018-09-19 |
Cold Spring Harbor Laboratory |
Gezielten erhöhung der nukleären genleistung
|
SG11201702877TA
(en)
|
2014-10-10 |
2017-05-30 |
Hoffmann La Roche |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
US10364433B2
(en)
|
2014-11-14 |
2019-07-30 |
The Regents Of The University Of California |
Modulation of AGPAT5 expression
|
EP3020813A1
(de)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-Oligonukleotide als Inhibitoren der TGF-R-Signalgebung
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
US10400243B2
(en)
|
2014-11-25 |
2019-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of UBE3A-ATS expression
|
CA2970177C
(en)
|
2014-12-08 |
2023-09-19 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
EP3234131B1
(de)
|
2014-12-16 |
2020-04-22 |
Roche Innovation Center Copenhagen A/S |
Verfahren zum screening von chrialer toxizität
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
US11761951B2
(en)
|
2015-02-04 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
MX2017010066A
(es)
|
2015-02-04 |
2017-11-01 |
Hoffmann La Roche |
Oligomeros antisentido de tau y usos de los mismos.
|
AU2016219263B2
(en)
|
2015-02-13 |
2022-12-01 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
|
BR112017017178A2
(pt)
|
2015-02-26 |
2018-04-03 |
Ionis Pharmaceuticals Inc |
moduladores específicos de alelo de rodopsina de p23h
|
DK3265564T3
(da)
|
2015-03-03 |
2022-04-11 |
Ionis Pharmaceuticals Inc |
Fremgangsmåde til modulering af mecp2-ekspression
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
EP3265098A4
(de)
|
2015-03-03 |
2019-02-13 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen zur modulierung der mecp2 -expression
|
AU2016244106B2
(en)
|
2015-04-03 |
2022-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating TMPRSS6 expression
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
KR102104163B1
(ko)
|
2015-04-16 |
2020-04-23 |
아이오니스 파마수티컬즈, 인코포레이티드 |
C9orf72 발현을 조절하기 위한 조성물
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3310918B1
(de)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
JP2018519811A
(ja)
|
2015-06-29 |
2018-07-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾crispr rna及び修飾単一crispr rnaならびにその使用
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
IL256622B2
(en)
|
2015-07-10 |
2023-09-01 |
Ionis Pharmaceuticals Inc |
Modulators of diacylglycerol acyltransferase 2 (dgat2)
|
WO2017024111A1
(en)
|
2015-08-04 |
2017-02-09 |
The University Of Chicago |
Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
JP7028764B2
(ja)
|
2015-09-02 |
2022-03-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プログラム細胞死1リガンド1(PD-L1)iRNA組成物およびその使用方法
|
KR20240027890A
(ko)
|
2015-09-14 |
2024-03-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
지질양이온성 덴드리머 및 이의 용도
|
CA2999177A1
(en)
|
2015-09-24 |
2017-03-30 |
The Regents Of The University Of California |
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
|
AU2016326619B2
(en)
|
2015-09-24 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of KRAS expression
|
EP4285912A2
(de)
|
2015-09-25 |
2023-12-06 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
|
BR122020023854B1
(pt)
|
2015-10-08 |
2022-11-29 |
Ionis Pharmaceuticals, Inc |
Composto compreendendo oligonucleotídeo modificado e seu uso, uso do oligonucleotídeo modificado, composição e seu uso
|
IL308174A
(en)
|
2015-10-09 |
2024-01-01 |
Univ Southampton |
Gene expression modulation and dysregulated protein expression scanning
|
US10955407B2
(en)
|
2015-10-22 |
2021-03-23 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
US11260073B2
(en)
|
2015-11-02 |
2022-03-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating C90RF72
|
EP4119569A1
(de)
|
2015-11-06 |
2023-01-18 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen zur verwendung in der therapie
|
MX2018005277A
(es)
|
2015-11-06 |
2018-08-01 |
Ionis Pharmaceuticals Inc |
Modular la expresion de apolipoproteina (a).
|
CN116064540A
(zh)
|
2015-11-12 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
用于诱导父本ube3a表达的寡核苷酸
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
JP7049248B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
常染色体優性精神遅滞-5とドラベ症候群の処置のためのアンチセンスオリゴマー
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
WO2017156242A1
(en)
|
2016-03-09 |
2017-09-14 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting pmp22 expression
|
SG11201807854SA
(en)
|
2016-03-14 |
2018-10-30 |
Hoffmann La Roche |
Oligonucleotides for reduction of pd-l1 expression
|
US10961271B2
(en)
|
2016-03-16 |
2021-03-30 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
ES2933435T3
(es)
|
2016-04-13 |
2023-02-08 |
Ionis Pharmaceuticals Inc |
Métodos para reducir la expresión de C9ORF72
|
KR102468177B1
(ko)
|
2016-04-14 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
트리틸-모노-GalNAc 화합물 및 이의 용도
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
JP7080826B2
(ja)
|
2016-05-16 |
2022-06-06 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
EP3472348B1
(de)
|
2016-06-17 |
2022-06-29 |
F. Hoffmann-La Roche AG |
In-vitro-screeningtests für nephrotoxizität
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
CN109312403B
(zh)
|
2016-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
体外肾毒性筛选测定法
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
EP4163293A1
(de)
|
2016-06-24 |
2023-04-12 |
The Scripps Research Institute |
Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
|
TW201803990A
(zh)
|
2016-07-01 |
2018-02-01 |
赫孚孟拉羅股份公司 |
用於調節htra1表現之反股寡核苷酸
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
IL308256A
(en)
|
2016-07-15 |
2024-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating SMN2
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
EP3538671A1
(de)
|
2016-11-11 |
2019-09-18 |
Roche Innovation Center Copenhagen A/S |
Erfassung und erkennung therapeutischer oligonukleotide
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
EP3568481A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der relb-expression
|
EP3568480A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der nfkb2-expression
|
WO2018130582A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
EP3568477A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der rela-expression
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
CA3059446A1
(en)
|
2017-04-18 |
2018-10-25 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
US11401519B2
(en)
|
2017-06-07 |
2022-08-02 |
University Of Massachusetts |
Anti-ADAM33 oligonucleotides and related methods
|
WO2019014267A1
(en)
|
2017-07-11 |
2019-01-17 |
Synthorx, Inc. |
INCORPORATION OF NON-NATURAL NUCLEOTIDES AND ASSOCIATED METHODS
|
EP3652317A1
(de)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
|
JP2020529976A
(ja)
|
2017-08-03 |
2020-10-15 |
シンソークス,インク. |
自己免疫疾患の処置のためのサイトカイン抱合体
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
EP3668984A4
(de)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
KR20240035631A
(ko)
|
2017-08-25 |
2024-03-15 |
스톡 테라퓨틱스, 인크. |
병태 및 질환 치료용 안티센스 올리고머
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
SG11202003461TA
(en)
|
2017-10-16 |
2020-05-28 |
Hoffmann La Roche |
NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
EP3724333A2
(de)
|
2017-12-11 |
2020-10-21 |
Roche Innovation Center Copenhagen A/S |
Oligonukleotide zur modulierung der fndc3b-expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
WO2019118916A1
(en)
|
2017-12-14 |
2019-06-20 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
EA202091520A1
(ru)
|
2017-12-18 |
2020-10-05 |
Элнилэм Фармасьютикалз, Инк. |
Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
JP2021507253A
(ja)
|
2017-12-21 |
2021-02-22 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Htra1 rnaアンタゴニストについてのコンパニオン診断
|
JP7476101B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド
|
KR20200104302A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 티오포스포르아미다이트
|
JP7476102B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド
|
US20210095274A1
(en)
|
2018-01-10 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
PE20211749A1
(es)
|
2018-01-12 |
2021-09-06 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
|
PE20210172A1
(es)
|
2018-01-12 |
2021-01-29 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos
|
EP3737387A1
(de)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antisense oligonukleotide zum targeting von alpha-synuklein und deren verwendung
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Gsk3b発現を調節するためのオリゴヌクレオチド
|
CN111902537A
(zh)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Dnm2表达的调节剂
|
JP2021510525A
(ja)
|
2018-01-17 |
2021-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Erc1発現を調節するためのオリゴヌクレオチド
|
CN111655851A
(zh)
|
2018-01-18 |
2020-09-11 |
哥本哈根罗氏创新中心 |
靶向srebp1的反义寡核苷酸
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
MA51795A
(fr)
|
2018-02-09 |
2020-12-16 |
Hoffmann La Roche |
Oligonucléotides pour moduler l'expression de tmem106b
|
CA3090901A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
AU2019226001A1
(en)
|
2018-02-21 |
2020-09-03 |
Bristol-Myers Squibb Company |
CAMK2D antisense oligonucleotides and uses thereof
|
BR112020017016A2
(pt)
|
2018-02-26 |
2020-12-29 |
Synthorx, Inc. |
Conjugados da il-15 e usos dos mesmos
|
SG11202007474YA
(en)
|
2018-03-02 |
2020-09-29 |
Ionis Pharmaceuticals Inc |
Modulators of irf4 expression
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
CA3094303A1
(en)
|
2018-03-20 |
2019-09-26 |
Tokyo Institute Of Technology |
Antisense oligonucleotide reduced in toxicity
|
EP3768694A4
(de)
|
2018-03-22 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur modulierung der fmr1-expression
|
AU2019247645A1
(en)
|
2018-04-05 |
2020-10-15 |
Centre Leon Berard |
Use of FUBP1 inhibitors for treating hepatitis B virus infection
|
CN112041440A
(zh)
|
2018-04-11 |
2020-12-04 |
Ionis制药公司 |
Ezh2表达的调节剂
|
SG11202008827XA
(en)
|
2018-04-13 |
2020-10-29 |
Bristol Myers Squibb Co |
Novel phosphorous (v)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (v) compounds
|
WO2019215066A1
(en)
|
2018-05-07 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
KR20210008497A
(ko)
|
2018-05-09 |
2021-01-22 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Atxn3 발현 감소용 화합물 및 방법
|
CN112041446B
(zh)
|
2018-05-09 |
2022-08-30 |
Ionis制药公司 |
用于减少fxi表达的化合物和方法
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
US20210220387A1
(en)
|
2018-05-18 |
2021-07-22 |
Hoffmann-La Roche, Inc. |
Pharmaceutical compositions for treatment of microrna related diseases
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
WO2019233922A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
JOP20200334A1
(ar)
|
2018-06-27 |
2020-12-20 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير الوراثي عن lrrk2
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
CA3103054A1
(en)
|
2018-07-03 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating tau expression
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
AU2019300324A1
(en)
|
2018-07-13 |
2021-01-21 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating RTEL1 expression
|
AR115847A1
(es)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de la atxn2
|
JP2021532075A
(ja)
|
2018-07-31 |
2021-11-25 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロトリチオエートヌクレオシド間結合を含むオリゴヌクレオチド
|
EP4122943A1
(de)
|
2018-07-31 |
2023-01-25 |
Roche Innovation Center Copenhagen A/S |
Oligonukleotide mit einer phosphordithioat-internukleosid-verknüpfung
|
JP2021533767A
(ja)
|
2018-08-13 |
2021-12-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
B型肝炎ウイルス(HBV)dsRNA物質組成物およびその使用方法
|
JP7476199B2
(ja)
|
2018-08-20 |
2024-04-30 |
ロジコン, インコーポレイテッド |
Scn1a脳症の治療のためのscn2aを標的とするアンチセンスオリゴヌクレオチド
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
WO2020038968A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
CN113728102A
(zh)
|
2018-08-28 |
2021-11-30 |
罗氏创新中心哥本哈根有限公司 |
使用剪接调节化合物进行新抗原工程化
|
EP3620519A1
(de)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
Tia1を標的とするアンチセンスオリゴヌクレオチド
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
JOP20210108A1
(ar)
|
2018-11-15 |
2023-01-30 |
Ionis Pharmaceuticals Inc |
معدِّلات تعبير irf5
|
JP7455831B2
(ja)
|
2018-11-21 |
2024-03-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
プリオン発現を低減するための化合物及び方法
|
JP7467457B2
(ja)
|
2018-11-22 |
2024-04-15 |
ロシュ イノベーション センター コペンハーゲン エーエス |
立体的に規定されたオリゴヌクレオチドの合成における活性化物質としてのピリジニウム塩
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
US20220042011A1
(en)
|
2018-12-21 |
2022-02-10 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotides targeting card9
|
WO2020150431A1
(en)
|
2019-01-16 |
2020-07-23 |
Genzyme Corporation |
Serpinc1 irna compositions and methods of use thereof
|
JP2022518500A
(ja)
|
2019-01-25 |
2022-03-15 |
エフ.ホフマン-ラ ロシュ アーゲー |
経口薬物送達のための脂質小胞
|
EP3917540A1
(de)
|
2019-01-31 |
2021-12-08 |
Ionis Pharmaceuticals, Inc. |
Modulatoren der yap1-expression
|
US20200246467A1
(en)
|
2019-02-06 |
2020-08-06 |
Synthorx, Inc. |
Il-2 conjugates and methods of use thereof
|
JP2022521510A
(ja)
|
2019-02-20 |
2022-04-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホノアセテートギャップマー型オリゴヌクレオチド
|
AU2020225336A1
(en)
|
2019-02-20 |
2021-08-19 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
CN113544271A
(zh)
|
2019-02-27 |
2021-10-22 |
Ionis制药公司 |
Malat1表达的调节剂
|
EP3941483A4
(de)
|
2019-03-21 |
2023-10-18 |
Arnay Sciences, Llc |
Antisense-oligonukleotide zur allelspezifität
|
SG11202109587TA
(en)
|
2019-03-21 |
2021-10-28 |
Codiak Biosciences Inc |
Extracellular vesicle conjugates and uses thereof
|
EP3950006A1
(de)
|
2019-03-29 |
2022-02-09 |
Mitsubishi Tanabe Pharma Corporation |
Verbindung, verfahren und pharmazeutische zusammensetzung zur einstellung der dux4-expression
|
KR20210144822A
(ko)
|
2019-03-29 |
2021-11-30 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ube3a-ats를 조절하기 위한 화합물 및 방법
|
KR20210149107A
(ko)
|
2019-04-03 |
2021-12-08 |
브리스톨-마이어스 스큅 컴퍼니 |
Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
WO2020201339A1
(en)
|
2019-04-04 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
US20220177509A1
(en)
*
|
2019-04-05 |
2022-06-09 |
Nippon Shokubai Co., Ltd. |
Production of bridged artificial nucleosides
|
US20220194976A1
(en)
|
2019-04-16 |
2022-06-23 |
Roche Innovation Center Copenhagen A/S |
Novel Process for Preparing Nucleotide P(V) Monomers
|
JP2022530537A
(ja)
|
2019-04-30 |
2022-06-29 |
ロシュ イノベーション センター コペンハーゲン エーエス |
レニウムキレート化mag3オリゴヌクレオチドを調製するための新規の方法
|
CN113795581A
(zh)
|
2019-05-03 |
2021-12-14 |
迪克纳制药公司 |
具有缩短的有义链的双链核酸抑制剂分子
|
WO2020243292A1
(en)
|
2019-05-28 |
2020-12-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fus expression
|
JP7155302B2
(ja)
|
2019-06-06 |
2022-10-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
Atxn3を標的とするアンチセンスオリゴヌクレオチド
|
CN114207129A
(zh)
|
2019-06-14 |
2022-03-18 |
斯克利普斯研究所 |
用于在半合成生物体中复制、转录和翻译的试剂和方法
|
CN110204583B
(zh)
*
|
2019-07-01 |
2021-03-23 |
中国人民解放军军事科学院军事医学研究院 |
修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2022544290A
(ja)
|
2019-08-14 |
2022-10-17 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
Krasを標的とするアンチセンスオリゴヌクレオチドを有する細胞外小胞
|
CN114729366A
(zh)
|
2019-08-14 |
2022-07-08 |
科迪亚克生物科学公司 |
靶向CEBP/β的细胞外囊泡-ASO构建体
|
BR112022002691A2
(pt)
|
2019-08-14 |
2022-08-23 |
Codiak Biosciences Inc |
Construtos de vesícula-aso extracelular visando stat6
|
CA3145924A1
(en)
|
2019-08-14 |
2021-02-18 |
Yi Zhang |
Extracellular vesicle linked to molecules and uses thereof
|
US20230132093A1
(en)
|
2019-08-14 |
2023-04-27 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
WO2021030769A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with nras antisense oligonucleotides
|
WO2021030778A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
CA3150163A1
(en)
|
2019-08-15 |
2021-02-18 |
Synthorx, Inc. |
Immuno oncology combination therapies with il-2 conjugates
|
BR112022003046A8
(pt)
|
2019-08-23 |
2024-02-06 |
Synthorx Inc |
Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
|
MX2022002740A
(es)
|
2019-09-10 |
2022-03-25 |
Synthorx Inc |
Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
|
EP4034247A1
(de)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting-agonisten mit exosomen zur behandlung von neuroimmunologischen erkrankungen
|
CN110590886B
(zh)
*
|
2019-09-26 |
2021-03-23 |
中国人民解放军军事科学院军事医学研究院 |
修饰核苷、核苷酸和核酸聚合物及其制备方法与应用
|
EP4045062A1
(de)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulatoren der pnpla3-expression
|
US20240141358A1
(en)
|
2019-10-18 |
2024-05-02 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
CN115176004A
(zh)
|
2019-10-22 |
2022-10-11 |
阿尔尼拉姆医药品有限公司 |
补体成分C3 iRNA组合物及其使用方法
|
MX2022004388A
(es)
|
2019-11-01 |
2022-05-06 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de arni de huntingtina (htt) y metodos de uso de las mismas.
|
CA3156405A1
(en)
|
2019-11-04 |
2021-05-14 |
Synthorx, Inc. |
Interleukin 10 conjugates and uses thereof
|
PE20230179A1
(es)
|
2019-11-13 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
EP4073251A1
(de)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
JP2023506547A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用
|
EP4077668A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von scamp3-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
|
EP4077671A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von saraf-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
|
WO2021122735A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sept9 inhibitors for treating hepatitis b virus infection
|
EP4077669A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von sbds-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
|
CN114829603A
(zh)
|
2019-12-20 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于抑制scn9a表达的增强寡核苷酸
|
CA3163646A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffman-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
EP4081639A1
(de)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
IL295496A
(en)
|
2020-02-18 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna preparations and methods of using them
|
WO2021167029A1
(ja)
*
|
2020-02-19 |
2021-08-26 |
国立大学法人大阪大学 |
架橋型ヌクレオシドおよびそれを用いたヌクレオチド
|
WO2021174019A1
(en)
|
2020-02-28 |
2021-09-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating smn2
|
EP4110916A1
(de)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonukleotide zum modulieren von cd73-exon-7-spleissen
|
TW202146651A
(zh)
|
2020-03-02 |
2021-12-16 |
日商田邊三菱製藥股份有限公司 |
miR-33b阻礙物質所致之動脈瘤的預防或治療
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
KR20220152270A
(ko)
|
2020-03-06 |
2022-11-15 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
|
BR112022017822A2
(pt)
|
2020-03-06 |
2022-11-08 |
Alnylam Pharmaceuticals Inc |
Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
MX2022012561A
(es)
|
2020-04-07 |
2022-11-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
MX2022013525A
(es)
|
2020-04-27 |
2023-01-24 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
|
IL297680A
(en)
|
2020-04-30 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
IRNA compounds complement factor b (cfb) and methods of using them
|
CN116096380A
(zh)
|
2020-05-01 |
2023-05-09 |
Ionis制药公司 |
调节atxn1的化合物和方法
|
WO2021231210A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
JP2023527684A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック, インコーポレイテッド |
神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法
|
CA3173647A1
(en)
|
2020-05-11 |
2021-11-18 |
Isabel AZNAREZ |
Opa1 antisense oligomers for treatment of conditions and diseases
|
WO2021230286A1
(ja)
|
2020-05-12 |
2021-11-18 |
田辺三菱製薬株式会社 |
Ataxin 3発現を調節するための化合物、方法及び医薬組成物
|
WO2021229036A1
(en)
|
2020-05-13 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Oligonucleotide agonists targeting progranulin
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
EP4150087A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
|
EP4150089A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
CN115884777A
(zh)
|
2020-05-22 |
2023-03-31 |
豪夫迈·罗氏有限公司 |
用于card9的剪接调节的寡核苷酸
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
WO2021257782A1
(en)
|
2020-06-18 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
KR20230027235A
(ko)
|
2020-06-25 |
2023-02-27 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
JP2023532518A
(ja)
|
2020-06-29 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Plp1を調節するための化合物及び方法
|
US20230272386A1
(en)
|
2020-07-17 |
2023-08-31 |
Mitsubishi Tanabe Pharma Corporation |
Agent for preventing or treating muscular disease
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
CN116209761A
(zh)
|
2020-07-23 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
靶向rna结合蛋白位点的寡核苷酸
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ. ホフマン-ラ ロシュ アーゲー |
B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP4225917A1
(de)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
MX2023004032A
(es)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Terapias inmuno-oncologicas con conjugados de il-2.
|
IL301611A
(en)
|
2020-10-09 |
2023-05-01 |
Synthorx Inc |
Combined immuno-oncology treatment with pairs of IL-2 and pembrolizumab
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2023549500A
(ja)
|
2020-11-13 |
2023-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
凝固第V因子(F5)iRNA組成物およびその使用方法
|
WO2022107025A1
(en)
|
2020-11-18 |
2022-05-27 |
Lemba Bv |
Umlilo antisense transcription inhibitors
|
AU2021381363A1
(en)
|
2020-11-18 |
2023-06-15 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
US20240002853A1
(en)
|
2020-11-23 |
2024-01-04 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
US20230060373A1
(en)
|
2020-12-03 |
2023-03-02 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
EP4259642A1
(de)
|
2020-12-08 |
2023-10-18 |
F. Hoffmann-La Roche AG |
Synthese von phosphordithioat-oligonukleotiden
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
JP2023553710A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
EP4291243A1
(de)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
|
TW202245843A
(zh)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
|
CA3210763A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
CA3207947A1
(en)
|
2021-02-17 |
2022-08-25 |
Aaron Noyes |
Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
|
IL305171A
(en)
|
2021-02-17 |
2023-10-01 |
Lonza Sales Ag |
EXTRACELLULAR VESILE-NLRP3 antagonist
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
TW202302847A
(zh)
|
2021-02-26 |
2023-01-16 |
美商艾拉倫製藥股份有限公司 |
己酮糖激酶(KHK)iRNA組成物及其使用方法
|
EP4301857A1
(de)
|
2021-03-04 |
2024-01-10 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
IL305873A
(en)
|
2021-04-01 |
2023-11-01 |
Lonza Sales Ag |
Extracellular vesicle compositions
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
KR20240001207A
(ko)
|
2021-04-26 |
2024-01-03 |
알닐람 파마슈티칼스 인코포레이티드 |
막관통 프로테아제, 세린 6(TMPRSS6) iRNA 조성물 및 이의 사용 방법
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
WO2022230987A1
(ja)
|
2021-04-30 |
2022-11-03 |
田辺三菱製薬株式会社 |
miR-33b阻害物質による筋疾患の予防又は治療
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CA3221935A1
(en)
|
2021-05-29 |
2022-12-08 |
1Globe Health Institute Llc |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
EP4347828A1
(de)
|
2021-05-29 |
2024-04-10 |
1Globe Health Institute LLC |
Kurze duplex-dna als neue gen-silencing-technologie und verwendung davon
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
TW202313117A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
|
IL308743A
(en)
|
2021-06-04 |
2024-01-01 |
Alnylam Pharmaceuticals Inc |
Compositions of human chromosome 9 open reading frame 72 iRNA factor (C9ORF72) and methods of using them
|
TW202313976A
(zh)
|
2021-06-08 |
2023-04-01 |
瑞士商赫孚孟拉羅股份公司 |
寡核苷酸顆粒蛋白前體促效劑
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
EP4105328A1
(de)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonukleotide zur prävention von nierenfunktionsstörungen, die durch endotheliale dysfunktion gefördert werden, durch unterdrückung von ephrin-b2
|
EP4355759A1
(de)
|
2021-06-18 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur reduzierung der ifnar1-expression
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
EP4363574A1
(de)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
EP4363580A1
(de)
|
2021-06-30 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung einer angiotensinogen- (gt-) assoziierten erkrankung
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
KR20240037293A
(ko)
|
2021-07-23 |
2024-03-21 |
알닐람 파마슈티칼스 인코포레이티드 |
베타-카테닌(CTNNB1) iRNA 조성물 및 이의 사용 방법
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其使用方法
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
IL310407A
(en)
|
2021-08-13 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Factor XII (F12) IRNA compositions and methods of using them
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
AR127158A1
(es)
|
2021-09-29 |
2023-12-27 |
Hoffmann La Roche |
Oligonucléotido antisentido para la edición de arn asociado a enfermedades de poliglutamina
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
AU2022384619A1
(en)
|
2021-11-11 |
2024-04-11 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023127857A1
(ja)
*
|
2021-12-27 |
2023-07-06 |
株式会社理研ジェネシス |
新規人工核酸、その製造方法及び用途
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023156652A1
(en)
|
2022-02-21 |
2023-08-24 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotide
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023222858A1
(en)
|
2022-05-18 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Improved oligonucleotides targeting rna binding protein sites
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(de)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|